Properly simulating an in vivo biological environment in vitro generally leads to increased clinical trial success and more rapid access to effective treatments. Microfluidics are a primary means of simulating biological environments in clinical and pharmaceutical laboratory research; however, the current utility of microfluidics is limited by materials and manufacturing challenges. Additive manufacturing (3D printing) has been heralded as the solution to these challenges, but it also faces hurdles, such as a relatively large minimum feature size and difficulty in removing excess build material from internal passages. Additive manufacturing has the potential to build complex, 3D, bio-mimicking structures and solve key challenges in microfluidics such as fabricating efficient mixing elements, incorporating of membranes or electrodes, providing integrated valving, and simplifying the connection between the micro-and macro-scales. However, the most promising and widely used material in microfluidics, PDMS, is currently not available for additive manufacturing. Phase, Inc. has developed a proprietary additive manufacturing technology termed electric field fabrication (EFF) based on liquid dielectrophoresis that shapes uncured PDMS into prescribed cross-sections which can be cured and bonded in succession to build a 3D microfluidic device. As opposed to other 3DP modalities, our patented approach offers unique control over the 3D printing process, opening the door to print new materials such as elastomerics with unprecedented resolution and no post- processing. This technology offers the potential to increase the design space of PDMS microfluidics to more closely match the in vivo environment enabling future advances in technologies such as organ-on-a- chip. Commercialization of an additive manufacturing platform for complex 3D PDMS microfluidic devices will enable broad access to 3D bio-mimicking structures which result in more effective treatments. The microfluidics market is now valued at $14 billion and is expected to grow to $31 billion by 2027. PDMS based products make up approximately 30% of the microfluidics market—the largest share of the market. The proposed Phase I effort will further enhance the fidelity of the EFF process for additively manufacturing PDMS devices through refinement of the overall platform and specifically address two aims which are foundational to the commercial viability of the process. The Phase I effort will 1) demonstrate the functional performance of a representative device and 2) demonstrate the ability to successfully incorporate a membrane into a microfluidic device. The aims of this Phase 1 SBIR proposal are to: Aim 1. Fabricate a representative 3D microfluidic device in PDMS. To demonstrate the broad ranging utility of the EFF process, a representative microfluid device will be fabricated in PDMS with two inlets, a passive mixing element, an observation/measurement channel and an outlet. Successful demonstration...